Efficacy and Durability of Combination Treatment With Glucagon-Like Peptide-1 Receptor Agonists and Basal Insulin-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and Durability of Combination Treatment With Glucagon-Like Peptide-1 Receptor Agonists and Basal Insulin

Published:2022-10-01 Issue:6 Volume:10 Page:42-45
ISSN:2633-559X
Container-title:ADCES in Practice
language:en
Short-container-title:ADCES in Practice

Author:

Martinez Anthony^ORCID,Goldman Jennifer D.^ORCID

Publisher

SAGE Publications

Subject

General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/2633559X221127992

Reference5 articles.

1. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022

2. Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know

3. Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes

4. Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta‐analysis

5. Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3